Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
Clinical trial NCT02262338 · COMPLETED
Trial details
- NCT number
- NCT02262338
- Sponsor
- ArmaGen, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2017-03-27
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.